EUVIMEDEUVIMED entdecken
Crossref

Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer

V. Hirsh

Current Oncology · 2012

DOI: 10.3747//co.19.959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2012. Verfasst von V. Hirsh.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Hirsh, V. (2012). Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer. Current Oncology. https://doi.org/10.3747//co.19.959

Vancouver

Hirsh V. Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer. Current Oncology. 2012. doi:10.3747//co.19.959

BibTeX
@article{Hirsh2012,
  author = {Hirsh, V.},
  title = {Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer},
  journal = {Current Oncology},
  year = {2012},
  doi = {10.3747//co.19.959}
}
Kostenlos starten →